Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AZA PH GL 2003 CL 001 - Extension A Multicenter, Randomized, Open-label, Parallel-group, Phase 3 Trial of Subcutaneous Azacitidine Plus Best Supportive Care Versus Conventional Care Regimens Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes (MDS)

NCT01186939 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT01186939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01186939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AZA PH GL 2003 CL 001 - Extension A Multicenter, Randomized, Open-label, Parallel-group, Phase 3 Trial of Subcutaneous Azacitidine Plus Best Supportive Care Versus Conventional Care Regimens Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes (MDS)
Lead sponsor
Celgene
Phase
Phase 3
Overall status
Completed
Start date
April 1, 2007
Completion date
September 1, 2009
Enrollment
40 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes